SynthesisBMC pulmonary medicine2024
Bronchial artery embolization versus conservative treatment for hemoptysis: a systematic review and meta-analysis.
Synthesis in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Prospective concordance of multidetector CT angiography and digital subtraction angiography in assessing bronchial artery morphology for hemoptysis embolization outcomes.The Libyan journal of medicine · 2026Article
- Pulmonary artery involvement contributes to the recurrence of hemoptysis after bronchial artery embolization in patients with chronic pulmonary aspergillosis.Journal of thoracic disease · 2026Article
- The hemodynamic and clinical characteristics of recurrent hemoptysis in bronchiectasis patients after vascular intervention procedures.Journal of thoracic disease · 2026Article
- Distinct bacterial profiles according to structural lung disease in patients undergoing bronchial artery embolization for hemoptysis.Frontiers in medicine · 2026Article
- Embosphere With or Without Coils in the Treatment of Hemoptysis: A Propensity-Matched Analysis of Recurrence and Safety.Canadian respiratory journal · 2026Article
- Non-massive versus massive hemoptysis and the impact of preoperative embolization in patients with destroyed lung parenchyma: a single-center experience.Journal of thoracic disease · 2025Article
- Clinical analysis of the efficacy of bronchial artery embolization with gelatin sponge in our hospital for cryptogenic hemoptysis: a single-center, retrospective, observational study.BMC pulmonary medicine · 2025Observational
- Bronchial Artery Embolisation in Haemoptysis Management: A Scoping Review with Emphasis on Embolic Materials and Indications.Advances in respiratory medicine · 2025Article
- Narrative review of the progress in the treatment of hemoptysis among patients with advanced lung cancer.Journal of thoracic disease · 2025Review
- The effect of Angio-CT on the efficacy of hemoptysis patients with non-bronchial systemic arteries-a retrospective study.Cardiovascular diagnosis and therapy · 2025Article
- Editorial: Case reports in thrombosis: 2024.Frontiers in cardiovascular medicine · 2025Article
- Early Recognition and Management of Acute Life-Threatening Haemoptysis in a Patient with Newly Diagnosed Tuberculosis.European journal of case reports in internal medicine · 2025Article
- Haemoptysis in a Patient with COPD Due to Right Bronchial Artery Dilation.European journal of case reports in internal medicine · 2025Article
- Development and validation of a novel nomogram for recurrent hemoptysis after bronchial artery embolization: a population-based cohort study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBronchial artery embolization (BAE) is currently an important treatment for hemoptysis. However, there is no consensus in the efficacy and safety of BAE compared to conservative treatment for hemoptysis, which limits the widespread use of BAE in hemoptysis. The objective was to assess the clinical benefit of BAE versus conservative treatment in patients with hemoptysis.
methodsA systematic search was conducted on the PubMed, Embase, ScienceDirect, CochraneLibrary, and ClinicalTrials up to March 2023. Both randomized controlled trials (RCTs) and cohort studies reporting rates of recurrent hemoptysis, clinical success, mortality, and complication by BAE and conservative treatment alone for hemoptysis were included. Data were pooled and compared by the use of odds ratio (OR) and 95% confidence interval (CI).
resultsTwelve studies (three RCTs, nine cohorts) involving 1231 patients met the eligibility criteria. Patients treated with BAE had lower recurrence rates of hemoptysis (26.5% vs. 34.6%; OR 0.37, 95% CI 0.14-0.98), higher clinical success rates (92.2% vs. 80.9%; OR 2.77, 95% CI 1.66-4.61), and lower hemoptysis-related mortality (0.8% vs. 3.2%; OR 0.20, 95% CI 0.05-0.84) compared with conservative treatment alone. There was no significant difference in all-cause mortality between the two groups. In terms of security, the incidence of major complications and minor complications in patients undergoing BAE treatment was 0.2% (1/422) and 15.6%, respectively.
conclusionsBAE was more effective than conservative treatment alone in controlling hemoptysis, reducing recurrence, and decreasing hemoptysis-related mortality, with an almost negligible risk of major complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.